
## **Danielle Brooks**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1727884/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Metabolic disease and adverse events from immune checkpoint inhibitors. European Journal of Endocrinology, 2021, 184, 857-865.	3.7	12
2	Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes. Diabetes Research and Clinical Practice, 2021, 172, 108633.	2.8	10
3	Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade. Cancer Treatment and Research Communications, 2020, 25, 100216.	1.7	6
4	Mycophenolate Mofetil and Plasmapheresis: A Treatment Option for Severe Insulin Resistance caused by Insulin Antibodies. AACE Clinical Case Reports, 2021, 7, 307-309.	1.1	2
5	Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor Journal of Clinical Oncology, 2020, 38, 480-480.	1.6	2
6	SAT-094 Overweight and Obesity Associated with Immune-Related Adverse Events in Patients on Immune Checkpoint Inhibitor Therapy. Journal of the Endocrine Society, 2019, 3, .	0.2	1
7	MON-603 Racial Distribution of Endocrine Complications in Oncology Patients Treated with Immune Checkpoint Inhibitors. Journal of the Endocrine Society, 2019, 3, .	0.2	0
8	Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors Journal of Clinical Oncology, 2020, 38, 482-482.	1.6	0
9	SAT-LB45 Chronic Opioid Use as a Cause of Severe Hypothyroidism: A Case Report. Journal of the Endocrine Society, 2020, 4, .	0.2	0